| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0006 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0008 |
| mRNA | Obatoclax Mesylate | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.001 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | 0.1 | 0.001 |
| mRNA | tubastatin A | GDSC1000 | pan-cancer | AAC | 0.097 | 0.001 |
| mRNA | Y-39983 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.002 |
| mRNA | FR-180204 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.002 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.002 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.1 | 0.002 |